AVXL Jan 2024 30.000 call
- GlobeNewswire
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to ANAVEX®2-73 pivotal trial for Parkinso
- Motley Fool
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.
- Zacks
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome
Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.
